XBIO on Nasdaq

Xenetic Biosciences (United States)

Logo: xeneticbio.com4

American pharmaceutical preparations company based in Lexington. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

2014Founded1

Compare with TherapeuticsMD, Inc., Upstream Bio, Inc. or Aptevo Therapeutics Inc., or pick any stock.

  • TickerXBIO on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersLexington1
  • Websitewww.xeneticbio.com
  • Incorporated inNV5
  • Business address945 Concord St., Framingham, Ma 017015
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • Legal formCorporation3
  • LEI5493002WV0KYX8JXAH523
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O WESTWARD LAW LLC, 89120 Las Vegas, United States3
  • Registered withBusiness Center (Secretary of State), E0450492011-83

See how the biggest companies compare on our leaderboards

Xenetic Biosciences (United States) image from its website
Image: xeneticbio.com4

The outcome and timing of the strategic review process being conducted by the Company’s Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process; the Company’s inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors; the potential for disruption to our business resulting from the review process; and potential adverse effects on the Company’s stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company’s current business operations, anticipated business strategy and product development plans.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-95.2%Operating margin7
-90.1%Net margin7
19.0%Revenue growth, 20257
-36.2%Return on equity7

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$3.1M

Out of $3.0M in revenue.7 The company lost money this year.

Financial statements

Revenue891011127$3.0M in 2025+17341% since 2019
0$1.0M$2.0M$3.0M2019: $17.1K$17.1K20192020: $436.9K$436.9K2020+2460%2021: $1.2M$1.2M2021+166%2022: $1.7M$1.7M2022+47%2023: $2.5M$2.5M2023+49%2024: $2.5M$2.5M2024−2%2025: $3.0M$3.0M2025+19%
Operating income891011127-$2.8M in 2025−78% since 2019
-$15.0M-$10.0M-$5.0M02019: -$12.9M-$12.9M20192020: -$13.9M-$13.9M2020+8%2021: -$5.7M-$5.7M2021−59%2022: -$6.7M-$6.7M2022+17%2023: -$4.5M-$4.5M2023−33%2024: -$4.2M-$4.2M2024−7%2025: -$2.8M-$2.8M2025−33%
Net income891011127-$2.7M in 2025−79% since 2019
-$15.0M-$10.0M-$5.0M02019: -$12.8M-$12.8M20192020: -$10.9M-$10.9M2020−15%2021: -$5.6M-$5.6M2021−48%2022: -$6.6M-$6.6M2022+16%2023: -$4.1M-$4.1M2023−37%2024: -$4.0M-$4.0M2024−4%2025: -$2.7M-$2.7M2025−32%

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Royalty revenue$3.0M$2.5M
Total revenue$3.0M$2.5M
Research and development-$3.1M-$3.3M
General and administrative-$2.7M-$3.4M
Total operating costs and expenses-$5.8M-$6.7M
Loss from operations-$2.8M-$4.2M
Other income (expense)$5.7K-$5.7K
Interest income, net$148.0K$249.9K
Total other income, net$153.7K$244.2K
Net loss-$2.7M-$4.0M
Basic net loss per share-$1.58-$2.57
Diluted net loss per share-$1.58-$2.57
Weighted-average shares of common stock outstanding, basic1.7M shares1.5M shares
Weighted-average shares of common stock outstanding, diluted1.7M shares1.5M shares

Compare Xenetic Biosciences (United States) with another company

Leadership

Who has led Xenetic Biosciences (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Scott Maguire2016–2017
  2. Jeffrey F. Eisenberg2017–2023
  3. James F. Parslow2024–now

Chief financial officer

  1. James F. Parslow2017–now

Chief operating officer

  1. Jeffrey F. Eisenberg2016
201520202025
Board members and other officers (13)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorAlexey Vinogradov named May 4, 2022 to Oct 13, 202233

Former names

  • General Sales & Leasing, Inc.Feb 27, 2013 to Jan 10, 20145
  • GENERAL AIRCRAFT INC.Nov 21, 2011 to Feb 12, 20135

Timeline

  1. Jun 21, 2024New chief executive James F. Parslow becomes CEO15
  2. Oct 30, 2017New chief executive Jeffrey F. Eisenberg becomes CEO16
  3. Dec 23, 2016New chief executive Michael Scott Maguire becomes CEO17
  4. 2014Founded Founded1

Filings

147 filings to the SEC since October 2021: 11 annual reports, 15 quarterly reports, 48 major events, 35 insider forms, 8 large holders, 2 private raises, 28 other. The latest 20:

  1. Sep 23, 20268-K CURRENT REPORT EDGAR
  2. Sep 18, 2026SCHEDULE 13G EDGAR
  3. Sep 16, 20268-K EDGAR
  4. Aug 7, 20268-K EDGAR
  5. Aug 6, 202610-Q FORM 10-Q FOR JUN 2026 EDGAR
  6. May 29, 2026SCHEDULE 13G EDGAR
  7. May 14, 2026SCHEDULE 13G/A EDGAR
  8. May 13, 20268-K EDGAR
  9. May 12, 202610-Q QUARTERLY REPORT FOR MARCH 2026 EDGAR
  10. Apr 24, 202610-K/A FORM 10-K FOR DEC 2025 AMENDMENT 1 EDGAR
  11. Apr 24, 20268-K CURRENT REPORT EDGAR
  12. Apr 23, 20264 EDGAR
  13. Mar 13, 20268-K CURRENT REPORT EDGAR
  14. Mar 12, 202610-K FORM 10-K FOR DEC 2025 EDGAR
  15. Feb 12, 2026SCHEDULE 13G EDGAR
  16. Jan 9, 20268-K EDGAR
  17. Jan 5, 20264 EDGAR
  18. Jan 5, 20264 EDGAR
  19. Jan 5, 20264 EDGAR
  20. Jan 5, 20264 EDGAR

The 147 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 12, 2022Raised $488,835 in a private offering of equity Form D: 1 investor so far Form D
  2. Apr 26, 2022Raised $866,250 in a private offering of equity Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Renaissance Technologies LLC117,440$341.8K0.0%−20,000
Geode Capital Management, LLC17,423$50.7K0.0%−4,018
Vanguard Capital Management LLC12,681$36.9K0.0%+5,950
SBI Securities Co., Ltd.1,000$2.9K0.0%New
Tower Research Capital LLC (TRC)696$2.0K0.0%−110
Morgan Stanley150$4370.0%New
JTC Employer Solutions Trustee Ltd2,700$80.0%No change
Darwin Wealth Management, LLC2$50.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36